

Silco Pharmaceuticals Limited
(As per Prospectus)

Nature of Business	Silco Pharmaceuticals limited has engaged in manufacturing and marketing of pharmaceuticals finished product in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Antipyretics, Anti Inflammatory Drugs, Antiulcer ants, Multi medicines which are sold in local market. It has set up a modern pharmaceutical plant that is equipped with advanced and modern machineries and technologies.	
Principal Products	The Company has following principal products: 1. Tablet; 2. Capsules; 3. Liquid Syrup; 4. Dry Syrup; 5. Pellet; 6. Powder; 7. Powder Suspension; 8. SRS Saline	
Security Trading Code	SILCOPHL	
BSEC's Consent for IPO	February 07, 2019	
Issue Date of Prospectus	February 11, 2019	
Subscription Open	March 07, 2019	
Subscription Close (Cut-off Date)	March 19, 2019	
Authorized Capital	Tk. 1,050,000,000	
Pre-IPO paid-up Capital	Tk. 643,700,000	
IPO size in shares	30,000,000	
IPO size in Tk. at face value	Tk. 300,000,000	
IPO size in Tk. at offer price	Tk. 300,000,000	
Post IPO Paid-up Capital	Tk. 943,700,000	
Face Value per share	Tk. 10.00	
Offer Price per share	Tk. 10.00	
Market Lot (Shares)	500	
Foreign Currency required for NRB and Foreign Applicants (per lot)	USD 60.10 or GBP 46.61 or EUR 53.36	
Use of IPO Proceeds	Construction of new factory building in the existing vacant area	144,655,552 (48.22%)
	Import of new Machinery	97,356,000.00 (32.45%)
	Purchase of Delivery Van	36,310,000.00 (12.10%)
	IPO Expenses	21,678,448.00 (7.23%)
	Total	300,000,000 (100.00%)
NAV per share	Tk. 27.05 as on June 30, 2018	
Earnings per Share (EPS)	Tk. 1.64 for the period ended on June 30, 2018	
Issue Managers	EBL Investments Limited, City Bank Capital Resources Limited & Citizen Securities & Investment Limited	
Auditor	Ahmad & Akhtar	
Website	www.Silcopharma.com	